Objective To evaluate the efficacy and toxicity of Docetaxel-Cisplatin-Fluorouracil（DCF） regimen and Nimotuzumab on treating advanced oral carcinoma. Methods  Nine patients with advanced oral carcinoma were collected and treated with the methods of DCF and Nimotuzumab in this study． All patients were given as follows: Nimotuzumab with 200 mg intravenous drip weekly for 6 weeks; Docetaxel and Cisplatin with 75 mg·m^-2 each only used on the first day; Fluorouracil with 750 mg·m^-2 infused continually for 8 hours from 1st to 5th day; the total cycle was 21 days. Results  All nine patients were evaluated for objective response. The response rate was 88.89％. The disease control rate was 100％. The major side effects were as follows: Bone marrow suppression, nausea, vomiting, alopecia and so on. Conclusion  The method of Nimotuzumab combining with DCF regimen was effective and safe on the treatment of advanced oral carcinoma. 

Nimotuzumab, oral carcinoma, Docetaxel, Cisplatin, Fluorouracil, chemotherapy